Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 08/10/23 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
114 |
| 08/10/23 | 8-K | Current report filing |
|
|
9 |
| 07/24/23 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 07/24/23 | 3 | Initial statement of beneficial ownership of securities |
|
2 | |
| 07/24/23 | 8-K | Current report filing |
|
|
31 |
| 07/19/23 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 07/19/23 | 144 | Filing for proposed sale of securities under Rule 144 |
|
3 | |
| 06/21/23 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 06/20/23 | 144 | Filing for proposed sale of securities under Rule 144 |
|
2 | |
| 06/20/23 | 144 | Filing for proposed sale of securities under Rule 144 |
|
2 |
